Wing Kit Lai

Department of Thrombosis and Vascular Diseases Laboratory, School of Health and Biomedical Sciences, STEM College, RMIT University, Bundoora, Victoria, Australia

Publications
  • Research Article   
    Risk of Haematologic Side Effects in Multiple Myeloma Patients Treated with Daratumumab
    Author(s): Wing Kit Lai and Denise E. Jackson*

    Background: Daratumumab is a novel monoclonal antibody (anti-CD38) drug that mainly for multiple myeloma patients. Hematologic adverse events are the most common in daratumumab-treated patients. However, the odds of daratumumab inducing the side effects have inadequate publications to support. This systematic review and meta- analysis were to investigate the hematologic safety of daratumumab. Methods: PubMed, EMBASE, Scopus, Cochrane library, Google Scholar were used for searching eligible clinical trials systematically from January 2010 to August 2021, only randomized case control trials were included. Results: Nine studies were included in the meta-analysis. The use of daratumumab associated with a lower risk of anemia (Odd Ratio [OR], 0.83; 95% Confidence Interval [CI], 0.72-0.96; I2=0%; P=0.01) but a significan.. View more»

    DOI: 10.4172/2155-9864.22.13.497

    Abstract HTML PDF